Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 13Terminated 6Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 51Carcinoma, Non-Small-Cell Lung 40Carcinoma, Renal Cell 27Carcinoma, Hepatocellular 18Neoplasms 15Neoplasm Metastasis 15Lung Neoplasms 14Colorectal Neoplasms 14Stomach Neoplasms 13Adenocarcinoma Of Esophagus 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Transitional Cell 8Brain Neoplasms 8Hodgkin Disease 7Skin Neoplasms 6Sarcoma 6Kidney Neoplasms 6Esophageal Neoplasms 6Triple Negative Breast Neoplasms 5Prostatic Neoplasms 5Pancreatic Neoplasms 5Clear-cell metastatic renal cell carcinoma 5Carcinoma, Merkel Cell 5Uveal Melanoma 4Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Nasopharyngeal Carcinoma 4Mesothelioma 4

Interventions

zaleplon 1olaparib 1Rehabilitation 1Psychotherapy 1Paclitaxel 1Oxaliplatin 1Olanzapine 1Nivolumab 1Niacin 1Injections 1Health Services Needs and Demand 1Gemcitabine 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Cancer × Nivolumab × Clear all
NCT04495296 2025-12-19

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Suzhou Transcenta Therapeutics Co., Ltd.

Phase 1/2 Recruiting
320 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡